
傳媒天地
傳媒天地
新聞稿
-
-
PDF2018-10-01YYYY年MM月DD日Sanofi completes divestiture of Zentiva to Advent
-
PDF2018-09-28YYYY年MM月DD日FDA approves Libtayo as first and only treatment for advanced cutaneous squamous cell carcinoma
-
PDF2018-09-15YYYY年MM月DD日Positive Phase 3 results presented for Dupixent show significant improvement on multiple measures of disease sever
-
PDF2018-09-13YYYY年MM月DD日Sanofi to refocus two global business units
-
PDF2018-09-12YYYY年MM月DD日FDA to review supplemental Biologics License Application for Praluent Injection as potential treatment
-
PDF2018-09-04YYYY年MM月DD日Sanofi reaches civil settlement with US SEC
-
PDF2018-09-03YYYY年MM月DD日Cablivi approved in Europe for adults with acquired thrombotic thrombocytopenic purpura
-
PDF2018-07-31YYYY年MM月DD日Q2 2018 Performance Positions Sanofi for New Growth Phase
-
PDF2018-07-26YYYY年MM月DD日Sanofi Head of Human Resources Roberto Pucci to retire; Company names Caroline Luscombe to take over October 1<sup>st</sup>
-
PDF2018-06-29YYYY年MM月DD日CHMP recommends approval of Cablivi
-
PDF2018-06-28YYYY年MM月DD日Sanofi and Advent finalize negotiations for the acquisition of Zentiva
-
PDF2018-06-19YYYY年MM月DD日Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer
-
PDF2018-06-13YYYY年MM月DD日Sanofi successfully prices USD 2 billion bond issue
-
PDF2018-06-11YYYY年MM月DD日Sanofi Launches Action 2018, a Worldwide Employee Stock Purchase Plan
-
PDF2018-06-04YYYY年MM月DD日New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma
-
PDF2018-05-21YYYY年MM月DD日New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent improved moderate-to-severe
-
PDF2018-05-16YYYY年MM月DD日Dupixent<sup>®</sup> (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
-
PDF2018-01-19YYYY年MM月DD日FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
SAHK.SA.18.06.0174/APR2019